|
Patent
|
Title
|
Country |
|
|
MetaMouse
|
Nude mouse model for human
neoplastic disease
|
US
|
5,491,284
|
|
MetaMouse
|
Nude mouse model for human
neoplastic disease
|
US
|
5,569,812
Reissue RE:39,337 |
|
MetaMouse
|
Animal model for human disease |
Japan
|
2,664,261
|
|
MetaMouse
|
Animal model for human disease |
Europe
|
437,488
|
|
HDRA
|
Noncolorimetric histoculture
method for predicting drug response of tumors
|
US
|
5,474,909
|
|
HDRA
|
Native-state method and system
for determining viability and proliferative capacity of tissues in
vitro
|
US
|
5,726,009
|
|
HDRA
|
Expression profiling
based on histoculture
|
US
|
7,252,941
|
|
HDRA
|
Native-state method and system for determining viability and
proliferative capacity of tissues in vitro |
Europe
|
714,448 |
|
DermaTek
|
Native-state histoculturing
method for skin
|
US
|
5,849,579
|
|
DermaTek
|
Native-state histoculturing
method for skin
|
US
|
6,399,380
|
|
DermaTek
|
A native-state histoculturing
method for skin |
Europe
|
573,606
|
|
DermaTek
|
Method to provide for
production of hair coloring pigments in hair follicles
|
US
|
6,261,596
|
|
DermaTek
|
Method for delivering melanin
to hair follicles
|
US
|
5,641,508
|
|
DermaTek
|
Method to provide for
production of hair coloring
pigments in hair follicles
|
US
|
5,965,157
|
|
DermaTek
|
Method to introduce a
replacement pigment into the hair shaft through the hair follicle
|
US
|
6,224,901
|
|
DermaTek
|
Methods to deliver
macromolecules to hair follicles
|
US
|
5,914,126
|
|
DermaTek
|
Method to deliver compositions
conferring resistance to alopecia to hair
|
US
|
5,753,263
|
|
DermaTek
|
Method for delivering
beneficial compositions to hair follicles |
Canada
|
2159626
|
|
DermaTek
|
Method for delivering
beneficial compositions to hair follicles |
Europe
|
692972
|
|
DermaTek
|
Method for delivering
beneficial compositions to hair follicles |
Japan
|
2,950,519 |
|
DermaTek
|
Method for delivering
beneficial compositions to hair follicles |
Japan
|
2,950,520 |
|
DermaTek
|
Skin vibration method for
topical targeted delivery of beneficial agents into hair follicles
|
US
|
5,830,177
|
|
DermaTek
|
Skin vibration method for
topical targeted delivery of beneficial agents into hair follicles
|
US
|
6,080,127
|
|
DermaTek
|
Skin vibration method for
topical targeted delivery of beneficial agents into hair follicles |
Australia
|
731,559
|
|
DermaTek
|
Method
for promoting hair growth
|
US
|
6,733,776 |
|
DermaTek
|
Treatment
of alopecia
|
US
|
6,844,326 |
|
Methioninase
|
Methioninase gene therapy for
tumor treatment
|
US
|
6,524,571 |
|
Methioninase
|
Methioninase formulations and
use in diagnostic methods
|
US
|
6,231,854
|
|
Methioninase
|
Improved methioninase
formulations
|
US
|
5,888,506
|
|
Methioninase
|
Use of methioninase and
chemotherapy agents in chemotherapy |
US
|
5,690,929
|
|
Methioninase
|
Method to produce high levels
of methioninase
|
US
|
5,891,704
|
|
Methioninase
|
Use of methioninase as an
antitumor agent in antimethionine chemotherapy |
Europe |
668,933 |
|
Methioninase
|
High expression modules
containing two or more tandem copis of a methioninase encoding sequence |
Europe
|
1,005,557 |
|
Methioninase
|
High expression modules
containing two or more tandem copis of a methioninase encoding sequence |
Australia
|
752,107 |
|
Methioninase
|
Uses in methioninase as an
antitumor agent in anti-methionine chemotherapy |
Australia
|
687,768
|
|
Methioninase
|
Use of methioninase as an
antitumor agent in anti-methionine chemotherapy |
Japan
|
2,930,723
|
|
Methioninase
|
Recombinant L-methionine
gamma-lyase
|
US
|
5,861,154
|
|
Methioninase
|
Recombinant L-methionine
gamma-lyase
|
US
|
5,863,788
|
|
Methioninase
|
High expression modules
containing two or more tandem copies of a methioninase encoding sequence |
US
|
6,461,851 |
|
Methioninase
|
Modulators
of methylation for control of bacterial virulence |
US
|
6,632,430 |
|
Methioninase
|
Modulators
of methylation for control of bacterial virulence |
Europe
|
1183034 |
|
Methioninase
|
Lyase treatment for P.
carinii |
US
|
7,264,819 |
|
GFP
|
Metastasis models using green
fluorescent protein (GFP) as a marker
|
US
|
6,232,523
|
|
GFP
|
Metastasis models using green
fluorescent protein (GFP) as a marker
|
US
|
6,235,967
|
|
GFP
|
Metastasis models using green
fluorescent protein (GFP) as a marker
|
US
|
6,235,968
|
|
GFP
|
Metastasis models using green
fluorescent protein (GFP) as a marker
|
US
|
6,251,384
|
|
GFP
|
Metastasis models using green
fluorescent protein (GFP) as a marker
|
US
|
6,759,038 |
|
GFP
|
Whole-body
optical imaging of gene expression and uses thereof |
US
|
6,649,159 |
|
GFP
|
Real
time measurement of cellular responses
|
US
|
6,905,831
|
|
GFP
|
Metastasis model using green
fluorescent protein (GFP) as a marker |
Australia |
749,338 |
|
GFP
|
Whole-body
optical imaging of gene expression and uses thereof |
Australia |
2001249297 |
|
GFP
|
Metastasis model using green
fluorescent protein (GFP) as a marker |
Japan |
3,709,343 |
|
GFP
|
Whole-body
optical imaging of gene expression and uses thereof |
Japan |
4,021,197 |
|
Homocysteine Assay
|
High specificity
homocysteinases and genes therefor
|
US
|
6,140,102
|
|
Homocysteine Assay
|
High
specificity homocysteine assays for biological samples
|
US
|
5,985,540
|
|
Homocysteine Assay
|
High specificity homocysteine
assays for biological samples
|
US
|
5,998,191
|
|
Homocysteine Assay
|
High specificity homocysteine
assays for biological samples
|
US
|
6,066,467
|
|
Homocysteine Assay
|
Synthesis of N,N-disubstituted-P-Phenylenediamine
|
US
|
6,448,446
|
|
Homocysteine Assay
|
High
specificity homocysteinases |
US
|
6,468,762 |
|
Homocysteine Assay
|
High
expression and production of high specific activity
recombinant S-adenosylhomocysteine (SAHH) and improved assays for
S-adenosylmethionine (SAM) |
US
|
6,713,273 |
|
Homocysteine Assay
|
Synthesis of N,N-disubstituted-P-Phenylenediamine
|
Europe |
1265846
|
|
Homocysteine Assay
|
Homocysteine enzymatic assay kit |
Japan |
3,337,693 |
|
Homocysteine Assay
|
High specificity homocysteine assays for biological samples |
Australia |
758729 |
|
Homocysteine Assay
|
High specificity homocysteine assays for biological samples |
Australia |
758729 |
|
Homocysteine Assay
|
Synthesis
of N,N-disubstituted-P-Phenylenediamine
|
Australia |
2001229460
|
|
Homocysteine Assay
|
Synthesis
of N,N-disubstituted-P-Phenylenediamine
|
Korea |
10-0682292
|
|
Homocysteine
Therapy |
Use
of methioninase in anti-methionine and anti-homocysteine
chemotherapy
|
China |
ZL96190574.3
|
|
Cysteine Assay
|
Total
Cysteine Assay
|
US |
6,927,038
|
|
Cysteine Assay
|
Total
Cysteine Assay
|
China |
ZL02823051.5
|
|
Cysteine Assay
|
Total
Cysteine Assay
|
Europe |
1,456,399
|
|
Vitamin B6 Assay |
Homogeneous enzymatic assay for
vitamin B6 and improvements in H2S detection |
US
|
6,426,194 |
|
Vitamin B6 Assay |
Homogeneous enzymatic assay for
vitamin B6 and improvements in H2S detection |
Australia |
765,931 |
|
Folate Assay
|
Biological fluid assay methods
|
US
|
6,329,162
|
|
Folate Assay
|
Biological fluid assay methods
|
Europe |
1171630 |
|
Folate Assay
|
Biological fluid assay methods
|
Australia |
765,931 |
|
Folate Assay
|
Biological fluid assay methods
|
Australia |
2004200001 |
|
Folate Assay
|
Method
to determine hydrogen peroxide |
US
|
6,653,092
|
|
Homocysteine therapeutic
|
Methods for treating and
reducing the potential for cardiovascular disease using methioninase
compositions
|
US
|
5,715,835
|
|
Homocysteine therapeutic
|
Use
of methioninase in anti-methionine
and anti-homocysteine chemotherapy
|
Europe
|
0839055
|
|
Homocysteine therapeutic
|
Use of methioninase in
anti-methionine and anti-homocysteine chemotherapy
|
Australia
|
708,361
|
|
Hair Pigmentation
Gene Therapy
|
Method and model for hair
pigmentation
|
US
|
6,372,489
|
|
Gene Therapy
|
Selenium-containing
pro-drugs for cancer therapy |
US
|
6,653,278 |
|
Gene Therapy
|
Selenium-containing
pro-drugs for cancer therapy |
US
|
6,916,793 |
|
Gene Therapy
|
Methods for introducing genes into mammalian
subjects |
US
|
7,067,496 |
|
Gene Therapy
|
Selenium-containing
pro-drugs for cancer therapy |
Europe
|
1176968 |
|
Gene Therapy
|
Selenium-containing
pro-drugs for cancer therapy |
Australia |
784,612 |
|
In vitro model for HIV
infection and immune response |
Model for viral infection and
immune response |
US
|
6,551,772 |
|
In vitro model for HIV
infection and immune response |
In vitro model for HIV and
other viral diseases |
US
|
6,562,586 |
|
Dr.
Kate H. Murashige, of Morrison and Foerster, AntiCancer's patent
attorney, standing by AntiCancer's patent wall.
|